Next Article in Journal
Interferon α Therapy in Patients with Chronic Hepatitis C Infection: Quality of Life and Depression
Previous Article in Journal
Feasibility of Romiplostim Discontinuation in Adult Thrombopoietin-Receptor Agonist Responsive Patients with Primary Immune Thrombocytopenia: An Observational Retrospective Report in Real Life Clinical Practice
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 7
Issue 1
10.4081/hr.2015.5704
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma

by
Urmeel H. Patel
,
Muhammad A. Mir
,
Jeffrey K. Sivik
,
Divisha Raheja
,
Manoj K. Pandey
and
Giampaolo Talamo
*
Penn State Hershey Cancer Institute, 500 University Drive, Hershey, PA 17033, USA
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2015, 7(1), 5704; https://doi.org/10.4081/hr.2015.5704
Submission received: 7 November 2014 / Revised: 9 February 2015 / Accepted: 17 February 2015 / Published: 3 March 2015

Abstract

Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide. One of the most common side effects of thalidomide is neurotoxicity, predominantly in the form of peripheral neuropathy. We report 6 cases of significant central neurotoxicity associated with IMiD therapy. Treatment with thalidomide (1 patient), lenalidomide (4 patients), and pomalidomide (1 patient) was associated with various clinical manifestations of central neurotoxicity, including reversible coma, amnesia, expressive aphasia, and dysarthria. Central neurotoxicity should be recognized as an important side effect of IMiD therapy.
Keywords: multiple myeloma; central neurotoxicity; immunomodulatory drugs; thalidomide; lenalidomide; pomalidomide multiple myeloma; central neurotoxicity; immunomodulatory drugs; thalidomide; lenalidomide; pomalidomide

Share and Cite

MDPI and ACS Style

Patel, U.H.; Mir, M.A.; Sivik, J.K.; Raheja, D.; Pandey, M.K.; Talamo, G. Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma. Hematol. Rep. 2015, 7, 5704. https://doi.org/10.4081/hr.2015.5704

AMA Style

Patel UH, Mir MA, Sivik JK, Raheja D, Pandey MK, Talamo G. Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma. Hematology Reports. 2015; 7(1):5704. https://doi.org/10.4081/hr.2015.5704

Chicago/Turabian Style

Patel, Urmeel H., Muhammad A. Mir, Jeffrey K. Sivik, Divisha Raheja, Manoj K. Pandey, and Giampaolo Talamo. 2015. "Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma" Hematology Reports 7, no. 1: 5704. https://doi.org/10.4081/hr.2015.5704

APA Style

Patel, U. H., Mir, M. A., Sivik, J. K., Raheja, D., Pandey, M. K., & Talamo, G. (2015). Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma. Hematology Reports, 7(1), 5704. https://doi.org/10.4081/hr.2015.5704

Article Metrics

Back to TopTop